Continuum Advisory’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$335K Buy
+5,810
New +$334K 0.03% 367
2025
Q2
Sell
-3,268
Closed -$199K 549
2025
Q1
$199K Buy
3,268
+1,535
+89% +$89.5K 0.03% 391
2024
Q4
$98K Buy
1,733
+227
+15% +$12.7K 0.01% 520
2024
Q3
$88.1K Buy
1,506
+423
+39% +$19.8K 0.01% 550
2024
Q2
$45K Sell
1,083
-61,656
-98% -$2.76M 0.01% 626
2024
Q1
$2.81M Buy
+62,739
New +$3.2M 0.42% 51
2021
Q3
Sell
-4,099
Closed -$274K 296
2021
Q2
$274K Buy
+4,099
New +$267K 0.09% 221

Other funds holding BMY

Continuum Advisory's BMY Position: Q2 2026 in Review

Continuum Advisory opened a new position in Bristol-Myers Squibb (BMY) in Q2 2026: 5,810 shares worth $335K. The stake represents 0.03% of the portfolio and ranks #367 among its holdings. This is a return to the name: Continuum Advisory previously reported a position in BMY as recently as Q1 2025.

Continuum Advisory first reported a position in BMY in Q2 2021 and has held it in 7 quarters since. The position peaked at $2.81M in Q1 2024. 2,521 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Continuum Advisory held 5,810 shares of Bristol-Myers Squibb worth $335K as of Q2 2026.
  • Bristol-Myers Squibb was a new Continuum Advisory position in Q2 2026.
  • Bristol-Myers Squibb made up 0.03% of Continuum Advisory's portfolio in Q2 2026, its #367 holding.
  • Continuum Advisory first reported a position in Bristol-Myers Squibb in Q2 2021 and has held it in 7 quarters since.
  • Continuum Advisory's Bristol-Myers Squibb position peaked at $2.81M in Q1 2024.
  • 2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Continuum Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.